Dr Danielle Oh

Learn more about Monash Health’s Haematology team.

Dr Danielle Oh

Dr Danielle Oh is a clinical and laboratory haematologist and Adjunct Senior Lecturer at Monash University. She is the Clinical Lead for Cellular Therapies and Multiple Myeloma at Monash Health and serves as a Principal Investigator on several clinical trials in these areas. She also supports cellular therapy trials across other specialities, including Renal Medicine, Rheumatology and Oncology, as a sub-investigator, and serves as Honorary Medical Director at Hudson Institute Cell Therapies.

 

Dr Oh completed a clinical research fellowship at the Tom Baker Cancer Centre in Calgary, Canada, where her research in autologous stem cell transplantation was recognised with awards from both the American and Canadian Societies of Hematology. On returning to Australia, she completed a laboratory-based PhD at Monash University, characterising chimeric kinase/epigenetic inhibitors in preclinical models of lymphoma and multiple myeloma. Her research was supported by an NHMRC Postgraduate Scholarship and an HSANZ New Investigator Scholarship. She received the Albert Baikie Award for the best oral presentation by a new investigator at the HSANZ Annual Scientific Meeting and was awarded an Equity Trustees & Monash Partners Clinician Fellowship.

Publications

Oh DH, Ma X, Hogg SJ, He J, Kearney C, Brasacchio D, Susanto O, Maher B, Jennings IG, Newbold A, Fraser P, Gruber E, Kats LM, Gregory GP, Johnstone RW, Thompson PE, Shortt J. Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma. Proc Natl Acad Sci U S A. 2023 Sep 5;120(36):e2306414120.

Oh DH, Li H, Duan Q, Villa D, Peters A, Chua N, Owen CJ, Connors JM, Stewart DA. Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. Biol Blood Marrow Transplant. 2016 May;22(5):941-8.

Oh DH, Chua N, Street L, Stewart DA. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. Leuk Lymphoma. 2015 Mar 27:1-6.

Oh DH, Ghosh S, Chua N, Kostaras X, Tilley D, Chu M, Owen CJ, Stewart DA. Comparative effective analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis. Leuk Lymphoma. 2015 Jun;56(6):1756-62.

Shortt J, Oh DH, Opat SS. ADAMTS13 Antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013 Jan 3;368(1):90-2.

Our emergency departments are experiencing very high demand. Please consider alternative care options if it's urgent but not an emergency.Learn more
+